Oxford Immunotec Global PLC - Ordinary Shares (OXFD): Price and Financial Metrics


Oxford Immunotec Global PLC - Ordinary Shares (OXFD): $21.99

0.01 (+0.05%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

OXFD Stock Summary

  • For OXFD, its debt to operating expenses ratio is greater than that reported by merely 14.59% of US equities we're observing.
  • OXFD's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 9.49% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Oxford Immunotec Global PLC is reporting a growth rate of -119.75%; that's higher than only 16.38% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Oxford Immunotec Global PLC, a group of peers worth examining would be ATRI, CHFS, VAPO, SNES, and ALOT.
  • OXFD's SEC filings can be seen here. And to visit Oxford Immunotec Global PLC's official web site, go to www.oxfordimmunotec.com.

OXFD Stock Price Chart Interactive Chart >

Price chart for OXFD

OXFD Price/Volume Stats

Current price $21.99 52-week high $23.11
Prev. close $21.98 52-week low $8.37
Day low $21.97 Volume 808,500
Day high $21.99 Avg. volume 1,099,251
50-day MA $21.00 Dividend yield N/A
200-day MA $15.28 Market Cap 570.90M

Oxford Immunotec Global PLC - Ordinary Shares (OXFD) Company Bio


Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The company was founded in 2002 and is based in Abingdon, the United Kingdom.


OXFD Latest News Stream


Event/Time News Detail
Loading, please wait...

OXFD Latest Social Stream


Loading social stream, please wait...

View Full OXFD Social Stream

Latest OXFD News From Around the Web

Below are the latest news stories about Oxford Immunotec Global PLC that investors may wish to consider to help them evaluate OXFD as an investment opportunity.

Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection

Oxford Immunotec Global PLC (Nasdaq: OXFD) (the "Company"), a global, high-growth diagnostics company, announced that today it has released the T-SPOT.COVID test, a CE marked ELISPOT based test intended for qualitative detection of a cell mediated (T cell) immune response to SARS-CoV-2 in human whole blood. The company has filed an EUA request to the FDA for the test.

Yahoo | March 4, 2021

PerkinElmer, Inc. -- Moody's assigns Baa3 rating to PerkinElmer's notes offering

Rating Action: Moody's assigns Baa3 rating to PerkinElmer's notes offeringGlobal Credit Research - 04 Mar 2021New York, March 04, 2021 -- Moody's Investors Service, ("Moody's") assigned a Baa3 rating to the proposed offering of senior unsecured 10- and 30-year notes of PerkinElmer, Inc. ("PerkinElmer"). There are no changes to Moody's existing ratings of PerkinElmer including the Baa3 senior unsecured long-term rating. The acquisition slightly increases PerkinElmer's financial leverage to close to 3.0x, up from 2.5x in the last twelve months to September 30, 2020.

Yahoo | March 4, 2021

Lifshitz Law Firm, P.C. Announces Investigation of CHNG, MGLN, OBLN, and OXFD

NEW YORK, NY / ACCESSWIRE / February 14, 2021 / Lifshitz Law Firm, P. (NASDAQ:CHNG)Lifshitz Law Firm, P.

Yahoo | February 14, 2021

INVESTIGATION ALERT: Halper Sadeh LLP Investigates CUB, CRHM, GLUU, OXFD, OBLN; Shareholders Are Encouraged to Contact the Firm

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Yahoo | February 10, 2021

Oxford signs MOU with Green Cross Medical for T-SPOT Discovery SARS-CoV-2 kit

Oxford Immunotec (OXFD) announces it has worked with Green Cross Medical Science South Korea (GC MS) to enter into an MOU to market the research use only T-SPOT Discovery SARS-CoV-2 kit in South Korea.Under the agreement, GC MS will market and sell the product with Oxford Immunotec Korea providing overall support for the T-SPOT Discovery SARS-CoV-2...

Seeking Alpha | February 8, 2021

Read More 'OXFD' Stories Here

OXFD Price Returns

1-mo N/A
3-mo N/A
6-mo 0.64%
1-year 68.76%
3-year 85.26%
5-year 173.51%
YTD 25.91%
2020 5.21%
2019 29.89%
2018 -8.52%
2017 -6.56%
2016 30.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8048 seconds.